查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1891802

全球药物输送装置市场：依给药途径、应用、最终用户和地区划分 - 市场规模、行业趋势、机会分析和预测（2026-2035 年）

Global Drug Delivery Devices Market: By Route of Administration, Application, End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

药物输送装置市场正从稳定成长过渡到快速扩张期，反映出医疗保健产业日益增长的复杂性和创新性。 2025 年，该市场规模约为 2,126 亿美元，预计到 2035 年将成长近一倍，达到约 4,507 亿美元。这一成长意味着 2026 年至 2035 年预测期内的复合年增长率 (CAGR) 为 7.8%，显示在多种因素的共同推动下，市场呈现持续上升趋势。

推动市场快速扩张的主要因素之一是生物疗法的广泛应用，生物疗法在多种疾病的治疗中发挥越来越重要的作用。生物製剂的复杂性要求开发先进的注射装置，以便安全有效地传递这些强效药物，通常还需要精确的剂量控制和可控的释放机制。为此，製造商正在不断创新，研发用于这些先进疗法的新型给药系统，推动了对专业药物传输技术的需求。

值得关注的市场趋势

药物输送装置的竞争格局呈现出大型多元化医疗公司和专业创新企业并存的动态格局。这些企业正透过各种策略巩固其市场地位，包括併购、大力投资研发、建立策略联盟。这些发展正在推动产业整合，重塑竞争格局，并加剧争夺不断扩大的市场占有率的竞争。

2025年12月，飞利浦医疗（Phillips Medisize）——一家以其在药物输送、体外诊断和医疗器械的设计、开发、工程和製造方面的专业知识而闻名的Molex公司——将在着名的 "肺部药物输送" 大会（DDL 2025）上重点展示其吸入式药物输送装置和製剂平台。本次展览将展示飞利浦医疗在推动吸入疗法（药物传输技术的关键领域）的创新承诺和能力。

2025年10月初，Enable Injections宣布与Incyte建立重要的合作关係。 Incyte是一家领先的生物製药公司，根据InvestingPro报道，其估值达178亿美元，财务状况稳健。此合作的重点在于利用Enable公司的enFuse体外给药系统，开发并交付Incyte的在研疗法。

同月，全球领先的药物封装、药物递送和诊断解决方案提供者Stevanat集团宣布大幅扩大其药物递送系统产能。此举反映了该公司积极应对不断增长的市场需求，并顺应了扩大产能以满足医疗保健行业不断变化的需求的更广泛趋势。

核心成长驱动因子

药物递送设备市场的发展趋势与需要频繁、甚至终身服药的慢性疾病的增加密切相关。糖尿病、肥胖等慢性疾病以及需要复杂治疗方案的癌症已成为药物递送设备的主要需求来源。近年来，这些疾病的治疗方案发生了显着变化，许多患者已过渡到每週一次的自我注射。这项变更推动了对易于使用、可靠且能支持患者自主用药和依从性的给药装置的需求。

新机遇

给药装置市场正迅速向 "高价值解决方案" 类别转型，其特点是具备数位连接能力和复杂药物治疗方案管理能力。这些先进的装置旨在输送药物，并提供即时监测、数据采集以及与数位健康平台整合等高级功能。这一转变反映了个人化医疗和互联医疗的更广泛趋势，患者和医疗服务提供者都将受益于更精准、更具互动性的治疗方案。

优化障碍

严格的监管要求对给药装置市场的成长构成重大挑战。美国食品药物管理局 (FDA) 等监管机构制定了严格的标准，以确保所有进入市场的产品符合严格的安全性、有效性和品质标准。虽然这些法规对于保护患者健康和维护大众对医疗技术的信任至关重要，但它们也为寻求推出创新装置的製造商带来了重大障碍。

目录

第一章：摘要整理：全球药物传输设备市场

第二章：研究方法与架构

  • 研究目标
  • 产品概述
  • 市场区隔
  • 质性研究
    • 一手和二手资料来源
  • 量化研究
    • 一手和二手资料来源
  • 依地区划分的原始调查受访者
  • 研究假设
  • 市场规模估算
  • 资料三角验证

第三章：全球药物传输设备市场概论

  • 产业价值链分析
    • 材料供应商
    • 製造商
    • 经销商
    • 终端用户
  • 行业展望
  • PESTLE 分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场成长与展望
    • 市场收入估计与预测（2020-2035）
    • 价格趋势分析
  • 市场吸引力分析
    • 依细分市场/地理划分
    • 可操作的洞见（分析师建议）

第四章 竞争格局仪錶板

  • 市场集中度
  • 公司市占率分析（价值，2025 年）
  • 竞争格局及基准分析

第五章：全球药物输送装置市场分析

  • 市场动态与趋势
    • 成长驱动因素
    • 其他因素
    • 机遇
    • 主要趋势
  • 市场规模及预测（2020-2035 年）
    • 依给药途径
    • 依应用
    • 依最终用户
    • 依地区

第六章：北美药物输送装置市场分析

第七章：欧洲药物输送装置市场分析

第八章：亚太地区药物输送装置市场分析

第九章：中东及非洲药物输送装置市场分析

第十章：南美洲药物输送装置市场分析

第十一章：公司简介

  • Becton, Dickinson and Company
  • 3M
  • Antares Pharma
  • Bayer AG
  • Cipla Inc.
  • Enable Injections
  • F. Hoffmann-La Roche Ltd
  • Gerresheimer AG
  • GlaxoSmithKline plc
  • Insulet Corporation
  • Johnson &Johnson Services, Inc.
  • MEDMIX SYSTEMS AG
  • Merck &Co., Inc.
  • Novartis AG
  • Novosanis
  • OraSure Technologies, Inc.
  • Pfizer Inc.
  • Sanofi
  • SMC Ltd.
  • Sulzer Ltd
  • ViVO Smart Medical Devices Ltd.
  • West Pharmaceutical Services, Inc.
  • Other Prominent Players

第12章 附录

简介目录
Product Code: AA12251594

The drug delivery devices market has moved beyond a phase of steady growth into a period of rapid expansion, reflecting the increasing complexity and innovation within the healthcare sector. Valued at approximately US$212.6 billion in 2025, the market is projected to nearly double in size, reaching an estimated valuation of US$450.7 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 7.8% over the forecast period from 2026 to 2035, indicating a strong and sustained upward trajectory driven by multiple converging factors.

One of the primary drivers behind this rapid market expansion is the proliferation of biologic therapies, which have become increasingly central to the treatment of a wide range of diseases. The complexity of biologics requires the development of advanced injectable devices capable of delivering these potent medications safely and effectively, often with precise dosing and controlled release mechanisms. In response, manufacturers are innovating new delivery systems that accommodate these sophisticated therapies, fueling demand for specialized drug delivery technologies.

Noteworthy Market Developments

The competitive landscape of the drug delivery devices market is characterized by a dynamic mix of large, diversified healthcare corporations alongside specialized innovators. These players employ a variety of strategies to strengthen their market positions, including mergers and acquisitions (M&A), significant investments in research and development (R&D), and the formation of strategic partnerships. Such activities are driving consolidation within the industry, reshaping the competitive hierarchy, and intensifying the race to capture larger shares of the expanding market.

In December 2025, Phillips Medisize, a Molex company renowned for its expertise in the design, development, engineering, and manufacturing of pharmaceutical drug delivery, in vitro diagnostic, and medtech devices, is set to highlight its inhaled drug delivery device and formulation platforms at the prestigious Drug Delivery to the Lungs conference (DDL 2025). This showcase will demonstrate Phillips Medisize's commitment to innovation and its capacity to advance the capabilities of inhalation therapies, a critical segment within drug delivery technology.

Earlier, in October 2025, a significant partnership was announced between biopharmaceutical giant Incyte, a company valued at $17.8 billion with strong financial health according to InvestingPro analysis, and Enable Injections. The collaboration focuses on leveraging Enable's enFuse On-Body Delivery System to develop and deliver Incyte's investigational therapies.

During the same month, Stevanato Group, a global leader providing drug containment, drug delivery, and diagnostic solutions across the pharmaceutical, biopharmaceutical, and life sciences sectors, announced a substantial expansion of its drug delivery system manufacturing capacity. This move reflects the company's proactive approach to meeting growing market demand and underscores the broader trend of scaling production capabilities to support the evolving needs of the healthcare industry.

Core Growth Drivers

The trajectory of the drug delivery devices market is closely intertwined with the rising prevalence of chronic diseases that necessitate frequent, often lifelong, medication dosing. Chronic conditions such as diabetes and obesity have emerged as the leading consumers of drug delivery devices, alongside cancer, which also requires complex therapeutic regimens. In recent years, treatment protocols for these diseases have evolved significantly, with many patients now shifting toward weekly self-injections. This change has increased the demand for user-friendly, reliable delivery devices that support patient autonomy and adherence to therapy.

Emerging Opportunity Trends

The drug delivery devices market is increasingly shifting toward what is known as "High-Value Solutions," a category of devices characterized by digital connectivity and the ability to manage complex drug formulations. These advanced devices are designed not only to deliver medication but also to provide enhanced functionality such as real-time monitoring, data collection, and integration with digital health platforms. This shift reflects a broader trend toward personalized medicine and connected healthcare, where patients and providers benefit from more precise and interactive treatment options.

Barriers to Optimization

Stringent regulatory requirements represent a major challenge to the growth of the drug delivery devices market. Regulatory agencies like the US Food and Drug Administration (FDA) impose rigorous standards designed to ensure that every product entering the market meets strict criteria for safety, efficacy, and quality. These regulations are essential to protect patient health and maintain trust in medical technologies, but they also create considerable hurdles for manufacturers seeking to introduce innovative devices.

Detailed Market Segmentation

By Route of Administration, Oral administration stands out as the undisputed leader in the drug delivery devices market, largely due to its unparalleled convenience and widespread acceptance among patients and healthcare providers alike. This route of administration offers a non-invasive, easy-to-use method for delivering medications, making it the preferred choice for a broad range of treatments. Its dominance is further reinforced by the vast number of small-molecule drugs, which are particularly well-suited for oral delivery because of their chemical properties and stability.

By Application, Cancer has emerged as the leading application within the drug delivery devices market due to the unique challenges associated with treating malignancies. Effective cancer treatment often requires the precise administration of highly potent and toxic biologic drugs, making accurate dosing and controlled delivery essential to maximize therapeutic outcomes while minimizing harmful side effects. The complexity of oncology therapies, which frequently involve targeted treatments and immunotherapies, has heightened the demand for advanced drug delivery devices capable of managing these sensitive medications with exceptional precision and safety.

By End User, Hospitals represent the largest end-user segment in the drug delivery devices market, primarily because they handle the highest volume of acute care procedures that demand the use of complex infusion systems. These procedures often require precise and reliable delivery of medications, fluids, and other therapies, making advanced drug delivery devices indispensable within hospital settings. The critical nature of hospital care, where timely and accurate drug administration can significantly impact patient outcomes, drives substantial demand for sophisticated delivery tools designed to meet stringent safety and efficacy standards.

Segment Breakdown

By Route of Administration

  • Oral
  • Ocular
  • Inhalation
  • Nasal
  • Injectable
  • Topical
  • Others

By Application

  • Cardiovascular
  • Diabetes
  • Cancer
  • Infectious Diseases
  • Others

By End User

  • Hospitals
  • Ambulatory Services
  • Home Healthcare

By Region

  • North America
  • The US
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a commanding position in the global drug delivery devices market, capturing a dominant market share of approximately 32.72% in 2025. This leadership is deeply rooted in the region's robust and structural growth driven by the rapid commercial expansion of high-value biologics. The increasing adoption of biologic therapies, which are often complex and require specialized delivery mechanisms, has significantly fueled the financial growth of the drug delivery devices sector in North America. This surge in therapeutic consumption underscores the region's pivotal role as a global hub for advanced healthcare solutions.
  • Beyond merely consuming these innovative therapies, North America is experiencing a manufacturing renaissance aimed at reshaping its pharmaceutical production landscape. There is a strong strategic push to localize manufacturing capabilities, bringing production closer to the regional market. This shift not only enhances supply chain resilience but also accelerates the delivery of advanced drug delivery devices to patients. By investing in state-of-the-art manufacturing technologies and infrastructure within its borders, North America is reinforcing its dominance in the drug delivery devices market.

Leading Market Participants

  • Becton, Dickinson and Company
  • 3M
  • Antares Pharma
  • Bayer AG
  • Cipla Inc.
  • Enable Injections
  • F. Hoffmann-La Roche Ltd
  • Gerresheimer AG
  • GlaxoSmithKline plc
  • Insulet Corporation
  • Johnson & Johnson Services, Inc.
  • MEDMIX SYSTEMS AG
  • Merck & Co., Inc.
  • Novartis AG
  • Novosanis
  • OraSure Technologies, Inc.
  • Pfizer Inc.
  • Sanofi
  • SMC Ltd.
  • Sulzer Ltd
  • ViVO Smart Medical Devices Ltd.
  • West Pharmaceutical Services, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Drug Delivery Devices Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Drug Delivery Devices Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Material Provider
    • 3.1.2. Manufacturer
    • 3.1.3. Distributor
    • 3.1.4. End User
  • 3.2. Industry Outlook
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Segment/Region
    • 3.6.2. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Drug Delivery Devices Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Route of Administration
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Oral
        • 5.2.1.1.2. Ocular
        • 5.2.1.1.3. Inhalation
        • 5.2.1.1.4. Nasal
        • 5.2.1.1.5. Injectable
        • 5.2.1.1.6. Topical
        • 5.2.1.1.7. Others
    • 5.2.2. By Application
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Cardiovascular
        • 5.2.2.1.2. Diabetes
        • 5.2.2.1.3. Cancer
        • 5.2.2.1.4. Infectious Diseases
        • 5.2.2.1.5. Others
    • 5.2.3. By End User
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Hospitals
        • 5.2.3.1.2. Ambulatory Services
        • 5.2.3.1.3. Home Healthcare
    • 5.2.4. By Region
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. North America
          • 5.2.4.1.1.1. The U.S.
          • 5.2.4.1.1.2. Canada
          • 5.2.4.1.1.3. Mexico
        • 5.2.4.1.2. Europe
          • 5.2.4.1.2.1. Western Europe
  • 5.2.4.1.2.1.1. The UK
  • 5.2.4.1.2.1.2. Germany
  • 5.2.4.1.2.1.3. France
  • 5.2.4.1.2.1.4. Italy
  • 5.2.4.1.2.1.5. Spain
  • 5.2.4.1.2.1.6. Rest of Western Europe
          • 5.2.4.1.2.2. Eastern Europe
  • 5.2.4.1.2.2.1. Poland
  • 5.2.4.1.2.2.2. Russia
  • 5.2.4.1.2.2.3. Rest of Eastern Europe
        • 5.2.4.1.3. Asia Pacific
          • 5.2.4.1.3.1. China
          • 5.2.4.1.3.2. India
          • 5.2.4.1.3.3. Japan
          • 5.2.4.1.3.4. South Korea
          • 5.2.4.1.3.5. Australia & New Zealand
          • 5.2.4.1.3.6. ASEAN
          • 5.2.4.1.3.7. Rest of Asia Pacific
        • 5.2.4.1.4. Middle East & Africa
          • 5.2.4.1.4.1. UAE
          • 5.2.4.1.4.2. Saudi Arabia
          • 5.2.4.1.4.3. South Africa
          • 5.2.4.1.4.4. Rest of MEA
        • 5.2.4.1.5. South America
          • 5.2.4.1.5.1. Argentina
          • 5.2.4.1.5.2. Brazil
          • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Drug Delivery Devices Market Analysis

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Route of Administration
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country

Chapter 7. Europe Drug Delivery Devices Market Analysis

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Route of Administration
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country

Chapter 8. Asia Pacific Drug Delivery Devices Market Analysis

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Route of Administration
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country

Chapter 9. Middle East & Africa Drug Delivery Devices Market Analysis

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Route of Administration
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country

Chapter 10. South America Drug Delivery Devices Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Route of Administration
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Becton, Dickinson and Company
  • 11.2. 3M
  • 11.3. Antares Pharma
  • 11.4. Bayer AG
  • 11.5. Cipla Inc.
  • 11.6. Enable Injections
  • 11.7. F. Hoffmann-La Roche Ltd
  • 11.8. Gerresheimer AG
  • 11.9. GlaxoSmithKline plc
  • 11.10. Insulet Corporation
  • 11.11. Johnson & Johnson Services, Inc.
  • 11.12. MEDMIX SYSTEMS AG
  • 11.13. Merck & Co., Inc.
  • 11.14. Novartis AG
  • 11.15. Novosanis
  • 11.16. OraSure Technologies, Inc.
  • 11.17. Pfizer Inc.
  • 11.18. Sanofi
  • 11.19. SMC Ltd.
  • 11.20. Sulzer Ltd
  • 11.21. ViVO Smart Medical Devices Ltd.
  • 11.22. West Pharmaceutical Services, Inc.
  • 11.23. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators